Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 28,842 shares changed hands during mid-day trading, a decline of 61% from the previous session's volume of 74,771 shares.The stock last traded at $12.35 and had previously closed at $11.90.
Gyre Therapeutics Stock Performance
The business's 50 day simple moving average is $12.74 and its 200-day simple moving average is $12.62.
Hedge Funds Weigh In On Gyre Therapeutics
Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after purchasing an additional 43,840 shares during the period. Charles Schwab Investment Management Inc. raised its position in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after acquiring an additional 90,557 shares in the last quarter. State Street Corp lifted its holdings in Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock valued at $1,310,000 after acquiring an additional 8,412 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics in the 3rd quarter valued at about $334,000. Finally, WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at about $220,000. Institutional investors and hedge funds own 23.99% of the company's stock.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
